84,091 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 84,091 shares of the company's stock, valued at approximately $995,000.

Other institutional investors also recently modified their holdings of the company. Russell Investments Group Ltd. grew its holdings in shares of Roivant Sciences by 478.6% in the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after acquiring an additional 1,948 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new position in shares of Roivant Sciences in the 4th quarter valued at $39,000. GAMMA Investing LLC increased its stake in Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after purchasing an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Roivant Sciences by 27.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after purchasing an additional 1,507 shares in the last quarter. Finally, Wells Fargo & Company MN raised its holdings in Roivant Sciences by 84.1% during the 4th quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock worth $89,000 after buying an additional 3,426 shares during the period. Institutional investors own 64.76% of the company's stock.

Wall Street Analysts Forecast Growth

ROIV has been the topic of several analyst reports. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Monday, April 21st.

Roivant Sciences Price Performance

NASDAQ:ROIV opened at $11.48 on Monday. The stock has a market cap of $8.19 billion, a PE ratio of -76.53 and a beta of 1.25. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $13.06. The stock's 50-day moving average is $10.42 and its two-hundred day moving average is $11.13.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, equities research analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Insider Buying and Selling

In related news, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the transaction, the chief accounting officer now owns 163,264 shares in the company, valued at approximately $1,702,843.52. This represents a 58.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $10.65, for a total transaction of $1,065,000.00. Following the completion of the sale, the chief operating officer now owns 896,869 shares of the company's stock, valued at $9,551,654.85. This trade represents a 10.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,395,541 shares of company stock worth $14,922,538. Corporate insiders own 7.90% of the company's stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.